CDTX · CIK 1610618
What Cidara Therapeutics, Inc. told the SEC could break it.
1 self-disclosed vulnerability, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for CDTX. More may follow as additional filings are processed.
In its own words
What could break it.
Geographic concentration
- China-based manufacturers/suppliers under U.S.–China trade restrictionsmedium
Some of Cidara's manufacturers and suppliers are located in China, exposing it to product-supply disruption and higher costs from escalating U.S.–China trade tensions; proposed U.S. legislation and sanctions targeting Chinese biotechnology companies could even prohibit Cidara from working with those vendors, cutting off supply of material.
“Some of our manufacturers and suppliers are located in China. Trade tensions and conflict between the United States and China have been escalating in recent years and, as such, we are exposed to the possibility of product supply disruption and increased costs and expenses in the event of changes to the laws, rules, regulations, and policies of the governments of the United States or China.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“We have generated all of our revenues from our strategic partnership with Janssen.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch